Matrifen® for Therapy of Severe Chronic Pain®
CompletedNCT00699335
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The aim of the study was to evaluate the efficacy and safety of Matrifen® in patients with severe and chronic pain who could only be sufficiently treated with opioid analgetics (WHO class 3).
Study details
- Official title
- Efficacy of Matrifen® in Patients Older Than 18 Years With Severe, Chronic Pain Including Quality of Life Questionnaire
- Conditions
- Severe Chronic Pain
- Interventions
- Sponsor
- Nycomed
- Start date
- 2008-06
- Primary completion
- 2009-07
- Sex
- All
- Age range
- from 18 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- Germany
- Total sites listed
- 1235
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Main inclusion criteria: * Outpatients with severe, chronic pain Main exclusion criteria: * Hypersensitivity to fentanyl * Co-administration of monoamineoxidase-inhibitors * Pregnancy * Respiratory depression * Chronic obstructive pulmonary disease (COPD) * Drug abuse * Impairment of CNS functions * Other criteria as defined in the Summary of Product Characteristics (Chapter 4.3)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00699335